Cat. #154639
ZH3D7:BCAR1 [D4E5] Fusion cell line
Cat. #: 154639
Sub-type: Continuous
Unit size: 1x10^6 cells / vial
Availability: 3-4 weeks
Organism: Human
Tissue: Breast
Disease: Cancer
Model: Cancer Model
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Lambert Dorssers
Institute: Erasmus University Medical Center (Erasmus MC)
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: ZH3D7:BCAR1 [D4E5] Fusion cell line
- Alternate name: Breast Cancer Anti-Estrogen Resistance 1; CASS1; P13Cas; CRKAS
- Cancer: Gynaecologic cancer
- Cancers detailed: Mammary ductal carcinoma
- Research fields: Cancer;Drug development
- Tool sub type: Continuous
- Parental cell: ZH3D7
- Organism: Human
- Tissue: Breast
- Disease: Cancer
- Model: Cancer Model
- Description: Breast cancer is widely and effectively treated with endocrine treatment. However, in many cases the tumours will eventually progress into an estrogen-independent and therapy-resistant phenotype. Somatic cell fusion was used to generate this cell line in order to elucidate the molecular mechanisms underlaying endocrine therapy failure. Using this method revealed that tamoxifen resistance co-segregated with only 1 or 2 of the integration loci present in the tamoxifen-resistant donor cell line, designated the first breast cancer anti-estrogen resistance locus (BCAR1)This cell line is part of a panel of 3 somatic hybrids (Cat No 154639-154641) plus the parental (Cat 154620).This cell line is a powerful tool for studying the molecular and cellular mechanisms of breast tumour progression and therapy resistance.
- Production details: Hygromycin-B-resistant variants of ZR-75-1 cells, ZH3D7, were used as recipients in the somatic-cell-fusion experiments. Donor cells were the anti-estrogen-resistant cell line XI-13. Approximately 6 million donor cells, which were gamma-irradiated with approx 40 Gy and 3 million recipient cells were plated in 25cm flasks in RBCS medium with estradiol. After strong adherence to the flasks in 36 to 48 hr, cells were washed 3 times in RPMI-1640 without serum and incubated with 1 ml polyethylene ...
- Biosafety level: 1
Target Details
- Target: BCAR1
Applications
- Application notes: This cell line is resistant to hygromycin and Genticin and are maintained in RBCS medium with estradiol and Geneticin. Since they carry a BCAR gene, that can also proliferate slowly in medium without estradiol and supplemented with anti-estrogen.
Handling
- Format: Frozen
- Growth medium: R/BCS medium containing estradiol and Geneticin (G418)
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice
- Storage conditions: Liquid Nitrogen
- Mycoplasma free: Yes
References
- Brinkman et al. 2000. J Natl Cancer Inst. 92(2):112-20. PMID: 10639512.
